Clinical Trial Update: Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma [Phase 4]

View source ↗

Summary

A Phase 4 trial update on icotinib as first-line and maintenance therapy for patients with EGFR-mutated non-small cell lung cancer (lung adenocarcinoma). The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma | Phase 4 | Status: UNKNOWN